Vestal Point Capital LP Invests $12.52 Million in Bruker Corporation $BRKR

Key Points

• Vestal Point Capital LP has acquired a new stake in Bruker Corporation with an investment of approximately $12.52 million, purchasing 300,000 shares during the first quarter.
• Bruker reported earnings of $0.32 per share for the latest quarter, just missing analysts' expectations of $0.33, with revenue totaling $797.40 million.
• The company recently announced a quarterly dividend of $0.05 per share, scheduled for payment on October 3rd, with an annualized yield of 0.6%.

Vestal Point Capital LP purchased a new stake in shares of Bruker Corporation (NASDAQ:BRKR - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 300,000 shares of the medical research company's stock, valued at approximately $12,522,000. Vestal Point Capital LP owned about 0.20% of Bruker at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in BRKR. Pinnacle Bancorp Inc. bought a new stake in shares of Bruker during the first quarter worth $29,000. Allworth Financial LP increased its holdings in Bruker by 92.4% in the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company's stock worth $30,000 after purchasing an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Bruker by 1,354.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company's stock valued at $33,000 after purchasing an additional 745 shares in the last quarter. Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Bruker during the first quarter worth about $42,000. Finally, MassMutual Private Wealth & Trust FSB increased its stake in shares of Bruker by 274.9% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 1,091 shares of the medical research company's stock valued at $46,000 after buying an additional 800 shares during the period. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Stock Up 3.5%

Shares of NASDAQ BRKR traded up $1.04 during trading on Friday, hitting $30.83. 8,539,948 shares of the company traded hands, compared to its average volume of 3,799,900. The firm has a market capitalization of $4.68 billion, a price-to-earnings ratio of 59.29, a P/E/G ratio of 3.71 and a beta of 1.21. The business's fifty day moving average is $37.12 and its 200 day moving average is $39.68. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.70 and a current ratio of 1.61. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $72.94.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Monday, August 4th. The medical research company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). The firm had revenue of $797.40 million during the quarter, compared to the consensus estimate of $811.17 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business's quarterly revenue was down .4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.52 earnings per share. Bruker has set its FY 2025 guidance at 1.950-2.050 EPS. Equities research analysts predict that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 3rd. Investors of record on Tuesday, September 23rd will be given a $0.05 dividend. The ex-dividend date of this dividend is Tuesday, September 23rd. This represents a $0.20 annualized dividend and a yield of 0.6%. Bruker's dividend payout ratio (DPR) is presently 38.46%.

Analyst Ratings Changes

Several equities analysts have issued reports on BRKR shares. Citigroup decreased their price target on shares of Bruker from $40.00 to $38.00 and set a "neutral" rating for the company in a research report on Monday, August 4th. Barclays decreased their price objective on Bruker from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Monday, August 4th. Stifel Nicolaus set a $40.00 price target on Bruker and gave the company a "hold" rating in a research report on Tuesday, August 5th. Jefferies Financial Group set a $60.00 price target on Bruker and gave the company a "buy" rating in a research note on Monday, August 4th. Finally, Wells Fargo & Company cut their price objective on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 5th. Five research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, Bruker currently has an average rating of "Hold" and an average price target of $51.30.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.